Qlife Receives U.S. Patent for Core Egoo Platform Technology
The United States Patent and Trademark Office (USPTO) has approved Qlife's patent application for its Egoo platform's core technology. This establishes patent protection in the U.S. and strengthens the company's global intellectual property position.
Swedish company Qlife Holding AB has secured a U.S. patent for the core technology behind its Egoo platform. The approval from the United States Patent and Trademark Office (USPTO) covers essential elements of the platform's architecture and analytical system, including the company's proprietary method for integrating sample mixing and optical measurement within a compact device.
The patent significantly strengthens Qlife's intellectual property position in the North American market and supports its strategic goals for global partnerships. The Egoo platform is designed to enable rapid and reliable diagnostic testing across various healthcare settings.
Qlife has previously obtained similar patents in other key markets, creating consistent protection for its innovations. The issuance of the U.S. patent opens new avenues for collaborations and broader adoption of the technology.
The company continues to focus on the development and commercialization of the Egoo platform, with the patent approval marking an important step in its growth strategy.